Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy.
J Pediatr
; 130(3): 470-4, 1997 Mar.
Article
em En
| MEDLINE
| ID: mdl-9063427
The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Hiperlipidemias
/
Síndrome Nefrótica
/
Hipolipemiantes
Tipo de estudo:
Etiology_studies
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
J Pediatr
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Arábia Saudita
País de publicação:
Estados Unidos